Search This Blog

Wednesday, April 29, 2020

Clinical Trial Begins to See if Convalescent Plasma Can Treat COVID-19

Montefiore Health System, Albert Einstein College of Medicine and NYU Langone have launched a new clinical trial to study if convalescent plasma—taken from people who have recovered from COVID-19—is effective in treating the disease.

The body’s immune response to viral infections includes making molecules called antibodies. Antibodies can combat the infection and possibly prevent reinfection in people—and may be successful for helping people who are sick with COVID-19 fight the virus. This therapy, known as convalescent plasma therapy, has been deployed in viral outbreaks over the past century, and has shown promise in reducing the severity of illness and improving survival rates.
The randomized controlled trial will enroll 300 people with COVID-19 respiratory symptoms. Half of these individuals will receive plasma that contains antibodies to the SARS-CoV-2 coronavirus, while the remaining half will receive a placebo. Candidates for the clinical trial have had respiratory symptoms for less than a week, require some supplemental oxygen or have been in the hospital for less than four days.
“We created this study based on evidence from the pre-antibiotic era, but there has been no scientific proof it is really effective,” said study co-leader Liise-anne Pirofski, M.D., chief of infectious diseases at Montefiore and Einstein and a leader of the national COVID-19 Convalescent Plasma Project.
Previous studies suggest that convalescent plasma may be helpful treatment for other coronaviruses, including SARS, but this trial aims to provide proof that it is effective for COVID-19 patients. Last month, Dr. Pirofski co-authored a widely cited viewpoint in the Journal of Clinical Investigation that championed the use of convalescent serum as a treatment for COVID-19.
https://www.biospace.com/article/releases/clinical-trial-begins-to-see-if-convalescent-plasma-can-treat-covid-19/

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.